M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
暂无分享,去创建一个
M. Shibuya | H. Saya | T. Suda | K. Kishi | Y. Kubota | K. Takubo | Takatsune Shimizu | Hiroaki Ohno
[1] D. Pieramici,et al. Anti-VEGF therapy: comparison of current and future agents , 2008, Eye.
[2] Fabian Kiessling,et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. , 2008, Cancer research.
[3] C. Stewart,et al. Leukemia inhibitory factor regulates microvessel density by modulating oxygen-dependent VEGF expression in mice. , 2008, The Journal of clinical investigation.
[4] MasabumiShibuya,et al. VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment , 2008 .
[5] N. Himes,et al. VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma , 2008, The Journal of experimental medicine.
[6] F. Peale,et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.
[7] M. Giacca,et al. Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.
[8] G. Fuh,et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.
[9] H. Verheul,et al. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition , 2007, Nature Reviews Cancer.
[10] Marcus Fruttiger,et al. Development of the retinal vasculature , 2007, Angiogenesis.
[11] Minhong Yan,et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.
[12] J. Pollard,et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.
[13] Yoshiko Kobayashi,et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model , 2006, Molecular Cancer Therapeutics.
[14] D. McDonald,et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.
[15] R. Schwendener,et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach , 2006, British Journal of Cancer.
[16] E. Stanley,et al. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. , 2006, Cancer research.
[17] D. Kerjaschki,et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants , 2006, Nature Medicine.
[18] T. Gardner,et al. Retinal angiogenesis in development and disease , 2005, Nature.
[19] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[20] Peter Carmeliet,et al. Angiogenesis in life, disease and medicine , 2005, Nature.
[21] Tatiana V. Petrova,et al. Lymphangiogenesis in development and human disease , 2005, Nature.
[22] Andrew P. McMahon,et al. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature , 2005, Nature.
[23] Seppo Ylä-Herttuala,et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. , 2005, The Journal of clinical investigation.
[24] G. Yancopoulos,et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets. , 2005, Cold Spring Harbor symposia on quantitative biology.
[25] E. Stanley,et al. Colony-Stimulating Factor-1 Blockade by Antisense Oligonucleotides and Small Interfering RNAs Suppresses Growth of Human Mammary Tumor Xenografts in Mice , 2004, Cancer Research.
[26] P. Rutkowski,et al. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis , 2003, Journal of surgical oncology.
[27] K. Alitalo,et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.
[28] K. Alitalo,et al. Double target for tumor mass destruction. , 2003, The Journal of clinical investigation.
[29] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Boulton,et al. The pathogenesis of diabetic retinopathy: old concepts and new questions , 2002, Eye.
[31] Andrew V. Nguyen,et al. Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.
[32] T. Noda,et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. , 2001, Cancer research.
[33] Z. Werb,et al. How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.
[34] H. Schreuder,et al. Osteosarcoma: Oncologic and functional results. A single institutional report covering 22 years , 1999, Journal of surgical oncology.
[35] E. Cagliero,et al. Fibronectin overexpression in retinal microvessels of patients with diabetes. , 1996, Investigative ophthalmology & visual science.
[36] S. Nishikawa,et al. Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M. , 1995, Oncogene.
[37] J. Pollard,et al. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. , 1994, Development.
[38] Lois E. H. Smith,et al. Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.
[39] Charles J. Sherr,et al. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1 , 1985, Cell.
[40] P. Lane,et al. Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. , 1976, The Journal of heredity.